Understanding the Financial Health of Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Company Overview - Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a key player in the medical technology sector, focusing on advanced silicone breast implants [1] Financial Performance - ESTA's Return on Invested Capital (ROIC) is -12.48%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 9.01%, indicating insufficient returns to cover capital costs [2] - The negative ROIC to WACC ratio for ESTA is -1.39, highlighting the company's challenges in generating adequate returns [2] Comparative Analysis - OrthoPediatrics Corp. (KIDS) has a ROIC of -6.27% and a WACC of 8.86%, resulting in a ROIC to WACC ratio of -0.71, which is better than ESTA's performance [3] - SI-BONE, Inc. (SIBN) shows a ROIC of -10.42% and a WACC of 7.50%, leading to a similar ROIC to WACC ratio of -1.39 as ESTA [3] - Crinetics Pharmaceuticals, Inc. (CRNX) faces a severe situation with a ROIC of -49.33% and a WACC of 4.44%, resulting in a ROIC to WACC ratio of -11.10 [4] - In contrast, LivaNova PLC (LIVN) has a positive ROIC of 10.90% and a WACC of 7.96%, achieving a favorable ROIC to WACC ratio of 1.37, indicating efficient capital utilization [4]